LGALS3 and coronary artery disorder: In this regard, in the CORONA trial, patients with coronary artery disease and left ventricular dysfunction responded to statin therapy only when NT-proBNP and galectin-3 levels were low, suggesting that, in patients with less myocardial damage, the vascular effects of statins still may improve the prognosis [10].